Aliases & Classifications for Rosacea

MalaCards integrated aliases for Rosacea:

Name: Rosacea 12 25 42 43 15 62 17 71 32
Erythematotelangiectatic Rosacea 25
Papulopustular Rosacea 25
Granulomatous Rosacea 25
Acne, Erythematosa 12
Phymatous Rosacea 25
Ocular Rosacea 25
Acne Roscea 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8881
ICD9CM 34 695.3
MeSH 43 D012393
NCIt 49 C97136
SNOMED-CT 67 398909004
ICD10 32 L71 L71.9
UMLS 71 C0035854

Summaries for Rosacea

Genetics Home Reference : 25 Rosacea is a long-lasting (chronic) skin disease that affects the face, primarily the forehead, nose, cheeks, and chin. The signs and symptoms of rosacea vary, and they may come and go or change over time. There are three main types of rosacea, categorized by their primary signs and symptoms. Erythematotelangiectatic rosacea causes skin redness and warmth (flushing) and visible clusters of blood vessels (telangiectasia). Papulopustular rosacea causes skin redness, swelling, and pus-filled bumps called pustules. Phymatous rosacea is characterized by thickened skin on the face and an enlarged, bulbous nose (rhinophyma). People with rosacea may feel itching, stinging, or burning sensations in affected areas. Often, the disorder affects the eyes, causing abnormal inflammation of the eyelids and eyes (ocular rosacea). This inflammation can cause dryness, redness, and irritation of the eyes and may affect vision.

MalaCards based summary : Rosacea, also known as erythematotelangiectatic rosacea, is related to blepharitis and dermatitis, and has symptoms including pruritus and exanthema. An important gene associated with Rosacea is CAMP (Cathelicidin Antimicrobial Peptide), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Isotretinoin and Hydroquinone have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and testes, and related phenotypes are hematopoietic system and homeostasis/metabolism

MedlinePlus : 42 Rosacea is a long-term disease that affects your skin and sometimes your eyes. It causes redness and pimples. Rosacea is most common in women and people with fair skin. It most often affects middle-aged and older adults. In most cases, rosacea only affects the face. Symptoms can include Frequent redness of the face, or flushing Small, red lines under the skin Acne A swollen nose Thick skin, usually on the forehead, chin, and cheeks Red, dry, itchy eyes and sometimes vision problems No one knows what causes rosacea. You may be more likely to have it if you blush a lot or if rosacea runs in your family. Rosacea is not dangerous. There is no cure, but treatments can help. They include medicines and sometimes surgery. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

PubMed Health : 62 About rosacea: Red patches of skin on your face, and tiny visible blood vessels and spots – these can be quite common symptoms. They may be caused by rosacea, a common facial skin inflammation. Skin diseases can be difficult to cope with, and they often affect people’s self-confidence and wellbeing. But if you have rosacea, there is a lot you can do on your own.

Wikipedia : 74 Rosacea is a long-term skin condition that typically affects the face. It results in redness, pimples,... more...

Related Diseases for Rosacea

Diseases related to Rosacea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 830)
# Related Disease Score Top Affiliating Genes
1 blepharitis 32.7 TNF MMP9 IL6 CCR6
2 dermatitis 31.1 TNF IL6 IL18 CXCL8 CCR6
3 keratoconjunctivitis 30.9 TNF MMP9 IL6 CXCL8
4 keratitis, hereditary 30.9 VEGFA TNF TLR2 IL6 CCR6
5 pustulosis of palm and sole 30.8 TNF CXCL8 CRP CCR6
6 lichen planus 30.8 TNF TLR2 IL6 CXCL8
7 hidradenitis suppurativa 30.7 TNF S100A8 CAMP
8 hidradenitis 30.7 TNF S100A8 CAMP
9 conjunctivitis 30.7 TNF MMP9 IL6 IL33 CXCL8
10 allergic contact dermatitis 30.7 TNF IL6 IL33 CXCL8
11 purpura 30.6 TNF IL6 CRP
12 sarcoidosis 1 30.6 TNF IL18 CRP CCR6
13 alopecia areata 30.5 VDR TNF IL6 IL18
14 cutaneous lupus erythematosus 30.5 TNF IL6 IL18
15 pyoderma 30.5 TNF MMP9 CXCL8 CRP CCR6
16 cheilitis 30.5 TNF MMP9 CCR6
17 venous insufficiency 30.4 VEGFA MMP9 CRP
18 contact dermatitis 30.4 TNF TLR2 IL6 IL33 IL18 CXCL8
19 allergic hypersensitivity disease 30.4 TNF IL33 CXCL8 CCR6
20 mental depression 30.4 TNF IL6 CRP
21 ulcerative colitis 30.3 TNF IL6 CXCL8 CRP CCR6
22 skin disease 30.3 VDR TNF TLR2 IL6 IL18 CXCL8
23 hypopyon 30.3 VEGFA TNF IL6 CRP
24 migraine with or without aura 1 30.3 TNF MMP9 IL6 GSTM1 CRP
25 trichomoniasis 30.3 TNF IL6 CXCL8
26 peptic ulcer disease 30.3 TNF S100A8 CXCL8
27 trachoma 30.3 VEGFA TNF IL6
28 crohn's colitis 30.3 TNF CXCL8 CCR6
29 fungal keratitis 30.2 TLR2 MMP9 MMP8
30 rhinitis 30.2 TNF IL6 IL33 CXCL8
31 erysipelas 30.2 TNF IL6 CRP
32 chronic venous insufficiency 30.2 VEGFA MMP9 CRP
33 gastritis 30.2 TNF S100A8 IL6 CXCL8 CCR6
34 syphilis 30.1 TNF IL6 CRP CCR6
35 keratoconus 30.1 TNF MMP9 MMP3 IL6
36 cutaneous leishmaniasis 30.1 TNF TLR2 IL6 CXCL8
37 impetigo 30.1 IL6 CCR6 CAMP
38 duodenal ulcer 30.0 TNF S100A8 IL6 CXCL8
39 dry eye syndrome 30.0 TNF S100A8 IL6 CCR6
40 mumps 30.0 TNF IL6 CXCL8
41 measles 30.0 TNF TLR2 IL6 CXCL8
42 marginal zone b-cell lymphoma 30.0 S100A8 IRF4 CCR6
43 colitis 30.0 TNF TLR2 IL6 IL18 CXCL8 CCR6
44 gastroesophageal reflux 30.0 TNF S100A8 IL6 CXCL8
45 fibromyalgia 30.0 TNF IL6 CXCL8 CRP
46 hashimoto thyroiditis 30.0 VDR TNF IL6 IL18
47 nasopharyngitis 30.0 TNF CRP CCR6
48 scabies 30.0 GSTM1 CXCL8 CCR6
49 exanthem 29.9 VEGFA TNF KDR IL6 CXCL8 CRP
50 chlamydia 29.9 TNF TLR2 IL6 IL18 CXCL8 CRP

Graphical network of the top 20 diseases related to Rosacea:



Diseases related to Rosacea

Symptoms & Phenotypes for Rosacea

UMLS symptoms related to Rosacea:


pruritus, exanthema

MGI Mouse Phenotypes related to Rosacea:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 CAMP CCR6 IL18 IL33 IL6 IRF4
2 homeostasis/metabolism MP:0005376 10.28 CCR6 CRP IL18 IL33 IL6 IRF4
3 cardiovascular system MP:0005385 10.26 ADSL CCR6 CRP IL18 IL6 KDR
4 immune system MP:0005387 10.24 CAMP CCR6 CRP IL18 IL33 IL6
5 digestive/alimentary MP:0005381 10.06 IL18 IL33 IL6 MMP9 TLR2 TNF
6 integument MP:0010771 9.97 IL18 IL33 IL6 KDR MMP9 TLR2
7 muscle MP:0005369 9.86 IL18 IL6 KDR MMP9 TLR2 TNF
8 neoplasm MP:0002006 9.7 IL6 IRF4 MMP8 MMP9 TLR2 TNF
9 skeleton MP:0005390 9.65 IL33 IL6 KDR KLK5 MMP3 MMP9
10 vision/eye MP:0005391 9.28 ADSL CAMP IL18 IL6 KDR KLK5

Drugs & Therapeutics for Rosacea

PubMed Health treatment related to Rosacea: 62

There are a lot of creams, lotions and gels recommended for the treatment of rosacea . Creams and gels with either azelaic acid or the antibiotic metronidazole in them are used most commonly. Antibiotics can also be taken as tablets, but then the entire body is affected.

Drugs for Rosacea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Isotretinoin Approved Phase 4 4759-48-2 5282379 5538
2
Hydroquinone Approved, Investigational Phase 4 123-31-9 785
3
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
4
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
5
Metronidazole Approved Phase 4 443-48-1 4173
6
Azelaic acid Approved Phase 4 123-99-9 2266
7
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
8
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
9
Adapalene Approved Phase 4 106685-40-9 60164
10
Sulfacetamide Approved Phase 4 144-80-9 5320
11
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
12
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
13
Phenylephrine Approved Phase 4 59-42-7 6041
14
Pseudoephedrine Approved Phase 4 90-82-4 7028
15
Ephedrine Approved Phase 4 299-42-3 9294
16
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
17
Aminolevulinic acid Approved Phase 4 106-60-5 137
18 Anti-Infective Agents Phase 4
19 Keratolytic Agents Phase 4
20 Antioxidants Phase 4
21 Radiation-Protective Agents Phase 4
22 Salicylates Phase 4
23 Cyclooxygenase Inhibitors Phase 4
24 Analgesics, Non-Narcotic Phase 4
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4
26 Anti-Bacterial Agents Phase 4
27 Adrenergic alpha-Agonists Phase 4
28 Adrenergic Agonists Phase 4
29 Immunologic Factors Phase 4
30 Immunosuppressive Agents Phase 4
31 Antifungal Agents Phase 4
32 Cyclosporins Phase 4
33 Calcineurin Inhibitors Phase 4
34 Ophthalmic Solutions Phase 4
35 Adapalene, Benzoyl Peroxide Drug Combination Phase 4
36 Brimonidine Tartrate Phase 4 70359-46-5
37 Antibiotics, Antitubercular Phase 4
38 Lubricant Eye Drops Phase 4
39 Anti-Allergic Agents Phase 4
40 Cardiotonic Agents Phase 4
41 Nasal Decongestants Phase 4
42 Vasoconstrictor Agents Phase 4
43 Sympathomimetics Phase 4
44 Protective Agents Phase 4
45 Mydriatics Phase 4
46 Photosensitizing Agents Phase 4
47
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
48
Oxytetracycline Approved, Investigational, Vet_approved Phase 2, Phase 3 79-57-2 54715139 5280972
49
Clindamycin Approved, Vet_approved Phase 2, Phase 3 18323-44-9 29029
50
tannic acid Approved Phase 3 1401-55-4

Interventional clinical trials:

(show top 50) (show all 194)
# Name Status NCT ID Phase Drugs
1 Intense Pulsed Light as an Adjunctive to Bromonidine for the Treatment of Rosacea- a Prospective Study Unknown status NCT03053700 Phase 4 Bromonide 0.33% gel
2 Efficacy & Safety of Azelaic Acid 15% Gel vs. Hydroquinone 4% Cream in the Treatment of Melasma Unknown status NCT00927771 Phase 4 azelaic acid gel;hydroquinone cream
3 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
4 Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea Completed NCT01872715 Phase 4 Oracea
5 A Multicenter, Double-Blind Clinical Trial to Assess the Efficacy and Tolerability of Topical Azelaic Acid 15% Gel Once Daily Compared to Topical Azelaic Acid 15% gelTwice Daily in Subjects With Papulopustular Rosacea Completed NCT00417937 Phase 4 azelaic acid 15% gel;azelaic acid 15% gel
6 Efficacy of Topical Cyclosporin 0.05% for the Treatment of Ocular Rosacea Completed NCT00348335 Phase 4 Cyclosporine 0.05%;Ocular lubricant
7 Azelaic Acid Foam 15% in the Treatment of Papulopustula Rosacea: An Evaluation of Photographic Evidence Completed NCT03418610 Phase 4 Azelaic Acid foam 15%
8 A Multicenter, Randomized, Double-blind, Placebo-controlled Evaluation of Rosacea-related Inflammatory Biochemical Markers in the Skin of Adults With Papulopustular Rosacea Treated With Daily Doxycycline 40 mg (30 mg Immediate Release / 10 mg Delayed Release Beads) Capsules Completed NCT01308619 Phase 4 Doxycycline
9 An Exploratory, Multicenter, Investigator-blinded, Active-controlled Study to Investigate the Efficacy of Topical Azelaic Acid (AzA)15% Gel Twice Daily or Metronidazole Topical Gel 1% Once Daily, Plus Anti-inflammatory Dose Doxycycline (40mg) Once Daily in Subjects With Moderate Papulopustular Rosacea Completed NCT00855595 Phase 4 Azelaic acid (Finacea, BAY39-6251);Metronidazole (Metrogel);Doxycycline (Oracea)
10 Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® Capsules Compared to Placebo After an Initial 12 Week Treatment Regimen With Oracea® and MetroGel® 1% in Adults With Rosacea Completed NCT01426269 Phase 4 Doxycycline;Metronidazole;Placebo
11 Phase IV An Evaluator-Blind Controlled Parallel-Group Study To Assess Efficacy And Safety Of Skinoren® 15% Gel And Differin® 0,1% Gel For The Treatment And Maintenance Treatment Of Facial Acne Vulgaris And Late-Type Acne In Females Completed NCT01387048 Phase 4 skinoren;differin;skinoren
12 MIRVASO® In Use Study: Managing Rosacea Through Assessment and Control of Its Erythema (The MIRACLE Study) Completed NCT02249065 Phase 4 Brimonidine
13 Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study Completed NCT02147691 Phase 4 Azelaic acid 15%;Brimonidine 0.33%
14 Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea Completed NCT02616250 Phase 4 Brimonidine 0.33% gel (Br);Ivermectin 1% cream (IVM)
15 Multicenter, Open-Label, Interventional Study on the Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Subjects With Rosacea Completed NCT03380390 Phase 4 Oxymetazoline HCL 1.0% Cream
16 Determine the Effects of COL-101 Administered Once Daily With Metronidazole Topical Gel, 1% Versus Doxycycline Hyclate 100 mg Administered Once Daily With Metronidazole Topical Gel, 1% in Patients With Moderate to Severe Rosacea Completed NCT00495313 Phase 4 doxycycline;doxycycline
17 A Phase 4, Open-Label, Multicenter, Community-based, 12-Week Trial Assessment of Effectiveness, Safety, and Subject Satisfaction With Oracea® [Doxycycline, USP] Capsules 40 mg (30 mg Immediate Release & 10 mg Delayed Release Beads) When Used as Monotherapy or as Add-On Therapy to Existing Topical Regimens for the Treatment of Rosacea Completed NCT00892281 Phase 4 doxycycline (Oracea®) 40 mg modified release as monotherapy;doxycycline (Oracea®) 40 mg modified release as add-on therapy
18 Efficacy Comparison of Ivermectin 1% Topical Cream Associated With Doxycycline 40 mg Modified Release (MR) Capsules Versus Ivermectin 1% Topical Cream Associated With Placebo in the Treatment of Severe Rosacea Completed NCT03075891 Phase 4 Ivermectin 1% cream;Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules
19 MetroGel 1% Hydration Study: A Kinetic Regression Study Completed NCT00436527 Phase 4 Metronidazole gel 1%
20 Internet Surveys and Their Impact on Adherence and Quality of Life to Mirvaso for Rosacea Completed NCT03048058 Phase 4 brimonidine topical gel 0.33% & survey;brimonidine topical gel 0.33% & SOC
21 Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis Completed NCT01456780 Phase 4 Loteprednol/tobramycin;Loteprednol;B+L Advanced Eye Relief Lubricant Drop
22 Topical Brimonidine Reduces IPL-induced Erythema Without Affecting Efficacy: a Randomized Controlled Trial in Patients With Facial Telangiectasias Completed NCT02761174 Phase 4 Brimonidine
23 Pilot Study to Evaluate Vbeam® Prima Pulsed Dye Laser (PDL) Treatment and RHOFADE® (Oxymetazoline HCL, 1% Cream) for Erythematotelangiectatic Rosacea Recruiting NCT04153188 Phase 4 Oxymetazoline HCL 1% Cream
24 Photodynamic Therapy for Papulopustular Rosacea Recruiting NCT02075671 Phase 4 Aminolevulinic acid topical solution 20%
25 Topical Timolol for the Treatment of Benign Vascular Periocular Lesions Withdrawn NCT01250457 Phase 4 topical Timolol
26 a Randomised, Double Blind, Placebo Controlled, Half- Face Study to Evaluate the Effect of Topical Ivermectin Cream 0.5% on Demodicidosis Unknown status NCT02036229 Phase 3 ivermectin cream 0.5%
27 The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial Unknown status NCT01809444 Phase 2, Phase 3 Prednisone+placebo of Doxycycline;Doxycycline+placebo of Prednisone
28 Prospective, Double-blind, Randomized, Controlled Clinical Trial of Low Dose Doxycycline in the Treatment of Corneal Burn Unknown status NCT01886560 Phase 2, Phase 3 Doxycycline;Placebo
29 A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Completed NCT03448939 Phase 3 S5G4T-1;S5G4T-2
30 A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea Completed NCT03564119 Phase 3 S5G4T-1;S5G4T-2
31 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (Ivermectin) Cream 1% (Galderma) in the Treatment of Moderate to Severe Papulopustular Rosacea Completed NCT02840461 Phase 3 Ivermectin Cream, 1%;Placebo/Vehicle cream
32 A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With a 4 Week Follow-up Period Completed NCT02576860 Phase 3 CLS001 (Omiganan);Vehicle
33 A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With an Open-Label Safety Extension Completed NCT02547441 Phase 3 CLS001 (Omiganan);Vehicle
34 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel-group Clinical Trial to Assess the Safety and Efficacy of Azelaic Acid Foam, 15% Topically Applied Twice Daily for 12 Weeks in Subjects With Papulopustular Rosacea Completed NCT01555463 Phase 3 Azelaic acid foam, 15% (BAY39-6251);Vehicle foam
35 A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea Completed NCT02576847 Phase 3 Omiganan
36 A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-11 and 12) Completed NCT03142451 Phase 3 FMX-103
37 A Multi Center, Open Label, Long Term Study of S5G4T-1 to Evaluate the Safety of S5G4T-1 in Papulopustular Rosacea Patients Completed NCT03564145 Phase 3 S5G4T-1
38 A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel. Completed NCT01494467 Phase 3 CD5024;Azelaic acid 15% Gel
39 Efficacy and Safety of CD5024 1% Cream Versus Metronidazole 0.75% Cream in Subjects With Papulopustular Rosacea Over 16 Weeks Treatment, Followed by a 36-week Extension Period. Completed NCT01493947 Phase 3 Ivermectin 1% cream;Metronidazole 0.75% cream
40 A Phase 3 Randomized, Double Blind, 12 Week Vehicle Controlled, Parallel Group Study Assessing the Efficacy and Safety of CD5024 1 % Cream Versus Vehicle Cream in Subjects With Papulopustular Rosacea, Followed by a 40 Week Investigator Blinded Extension Comparing the Long Term Safety of CD5024 1% Cream Versus Azelaic Acid 15 % Gel. Completed NCT01493687 Phase 3 CD5024;Azelaic acid 15% Gel
41 An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 Weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13) Completed NCT03276936 Phase 3 FMX103 1.5%
42 A Multi-center, Double-blind, Randomized, Vehicle-controlled, Parallel-group Study Comparing Metronidazole Gel 1%, to Metrogel® (Metronidazole Gel) 1% in the Treatment of Rosacea Completed NCT02393937 Phase 3 Reference: Metronidazole Gel 1%;Test: Metronidazole Gel 1%;Placebo Gel
43 A Double-Blind, Placebo-Controlled, Pilot Study to Determine the Safety and Efficacy of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel For The Treatment of Rosacea Over 12 Weeks Completed NCT00823901 Phase 2, Phase 3 Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel;Placebo gel
44 The Effect of Azelaic Acid (Financea Gel 15%) on Demodex Folliculorum Counts in Adult Subjects With Mild to Moderate Papulopustular Rosacea Completed NCT03035955 Phase 2, Phase 3 Azelaic acid
45 Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea Completed NCT02385240 Phase 3 Brimonidine Topical Gel, 0.33 percent (Perrigo);Brimonidine Topical Gel, 0.33 percent (Reference);Placebo gel
46 A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea Completed NCT00126399 Phase 3 doxycycline
47 Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face Completed NCT02800148 Phase 3 Azelaic acid foam;Azelaic acid foam;Azelaic acid foam - Placebo
48 Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea Completed NCT02795117 Phase 3 Ivermectin;Ivermectin (reference);Placebo
49 Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea Completed NCT03352323 Phase 3 Oxymetazoline
50 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Determine the Effects of Doxycycline Hyclate 20 Mg Tablets [Periostat(R)] Administered Twice Daily for the Treatment of Acne Rosacea Completed NCT00041977 Phase 3 doxycycline hyclate 20 mg twice daily

Search NIH Clinical Center for Rosacea

Inferred drug relations via UMLS 71 / NDF-RT 50 :


azelaic acid
Benzoyl Peroxide
Colloid sulfur
Loteprednol
loteprednol etabonate
Metronidazole
Metronidazole Hydrochloride
METRONIDAZOLE PWDR
resorcinol
RESORCINOL PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL

Cochrane evidence based reviews: rosacea

Genetic Tests for Rosacea

Anatomical Context for Rosacea

MalaCards organs/tissues related to Rosacea:

40
Skin, Eye, Testes, Liver, Small Intestine, Endothelial, Pituitary

Publications for Rosacea

Articles related to Rosacea:

(show top 50) (show all 3136)
# Title Authors PMID Year
1
Demodex folliculorum infestations in common facial dermatoses: acne vulgaris, rosacea, seborrheic dermatitis. 42 61
32113677 2020
2
Ecological niche differences between two polyploid cytotypes of Saxifraga rosacea. 61 42
32067225 2020
3
Bardolph's rosacea: skin disorders that define personality in Shakespeare's plays. 61 42
31896414 2019
4
Evaluation of serum uric acid levels in patients with rosacea. 61
32020322 2020
5
The efficacy and safety of permethrin 2.5% with tea tree oil gel on rosacea treatment: A double-blind, controlled clinical trial. 61
31613050 2020
6
Effectiveness of benzyl benzoate treatment on clinical symptoms and Demodex density over time in patients with rosacea and demodicosis: a real life retrospective follow-up study comparing low- and high-dose regimens. 61
32427504 2020
7
United States Stock Market Response to FDA Approval of New Dermatologic Drugs. 61
32574024 2020
8
Virtual Exams No Substitute for In-Person Care of Acne and Rosacea. 61
32574012 2020
9
Psychological Consequences of the Most Common Dermatoses: Data from the Objectifs Peau Study. 61
32449783 2020
10
Topical antibiotics in the dermatological clinical practice: indications, efficacy and adverse effects. 61
32531105 2020
11
Improved telangiectasia and reduced recurrence rate of rosacea after treatment with 540 nm-wavelength intense pulsed light: A prospective randomized controlled trial with a 2-year follow-up. 61
32346416 2020
12
Rosacea Patients Are at Higher Risk for Obstructive Sleep Apnea: Automated Retrospective Research. 61
32570669 2020
13
Bacterial and fungal microbiome characterization in patients with rosacea and healthy controls. 61
32533846 2020
14
Unilateral Periocular Intralymphatic Histiocytosis, Associated With Rosacea (Morbihan Disease). 61
31764086 2020
15
Relationship between rosacea and sleep. 61
32291809 2020
16
Value of GPSkin for the measurement of skin barrier impairment and for monitoring of rosacea treatment in daily practice. 61
32573826 2020
17
Rosacea and perioral dermatitis: a single-center retrospective analysis of the clinical presentation of 1032 patients. 61
32469453 2020
18
Rosacea treatment guideline for the Netherlands. 61
31970753 2020
19
Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee. 61
32035944 2020
20
Treating Inflammation in Rosacea: Current Options and Unmet Needs. 61
32574018 2020
21
Rosacea as a striking feature in family members with a STAT1 gain-of-function mutation. 61
31991004 2020
22
Evaluation of a simple image-based tool to quantify facial erythema in rosacea during treatment. 61
32537843 2020
23
Rosacea: a wholistic review and update from pathogenesis to diagnosis and therapy. 61
31880327 2020
24
Assessment of the abdominal fat index by ultrasonography in patients with rosacea. 61
32491195 2020
25
Efficacy and safety of hydroxychloroquine for treatment of patients with rosacea: a multi-center, randomized, double-blind, double-dummy, pilot study. 61
32439466 2020
26
Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials. 61
32004648 2020
27
Prevalence, clinical characteristics and health-related quality of life of rosacea in Chinese adolescents: a population-based study. 61
32362044 2020
28
An exploratory, open-label, investigator-initiated study of interleukin-17 blockade in patients with moderate-to-severe papulopustular rosacea. 61
32364247 2020
29
Rosacea is associated with conjoined interactions between physical barrier of the skin and microorganisms: A pilot study. 61
32419294 2020
30
Cutaneous Exophiala oligosperma infection presenting with multiple, rosacea-like papules on the cheek in a healthy individual. 61
32463524 2020
31
An altered fecal microbial profiling in rosacea patients compared to matched controls. 61
32446756 2020
32
Prevalence and risk factors of dry eye in 79,866 participants of the population-based Lifelines cohort study in the Netherlands. 61
32376389 2020
33
Demodex blepharokeratoconjunctivitis affecting young patients: A case series. 61
32317439 2020
34
Magnitude, characteristics and consequences of topical steroid misuse in rural North India: an observational study among dermatology outpatients. 61
32430446 2020
35
Expressions of glutathione S-transferase alpha, mu, pi, and theta in the skin samples of patients with acne rosacea. 61
32433803 2020
36
Ros-NET: A deep convolutional neural network for automatic identification of rosacea lesions. 61
31849118 2020
37
Alterations of Immune and Keratinization Gene Expression in Papulopustular Rosacea by Whole Transcriptome Analysis. 61
31705873 2020
38
Increased frequency of Demodex blepharitis in rosacea and facial demodicosis patients. 61
31553138 2020
39
Cigarette smoking and risk of rosacea: a nationwide population-based cohort study. 61
32401404 2020
40
Use of permethrin in the treatment of rosacea fulminans during pregnancy: One case report. 61
32306498 2020
41
Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel. 61
31392722 2020
42
Rosacea treatment: a patient-centric approach. 61
31773725 2020
43
Dapsone for Unresponsive Granulomatous Rosacea. 61
30946045 2020
44
Frontal Fibrosing Alopecia: A Retrospective Study of 75 Patients. 61
32417453 2020
45
Radiofrequency irradiation attenuates angiogenesis and inflammation in UVB-induced rosacea in mouse skin. 61
32434270 2020
46
Role of ferritin in pathogenesis of rosacea and its value in efficacy of 595 nm pulsed dye laser in treatment of different variants of rosacea: a clinical and immunohistochemical study. 61
32441163 2020
47
Oxymetazoline and Energy-Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open-Label, Interventional Study. 61
32378241 2020
48
Demodex positive discoid lupus erythematosus: Is it a separate entity or an overlap syndrome? 61
32275797 2020
49
Epidemiological features of rosacea in Changsha, China: A population-based, cross-sectional study. 61
32207167 2020
50
Use of beta-blockers for rosacea-associated facial erythema and flushing: a systematic review and update on proposed mode of action. 61
32360760 2020

Variations for Rosacea

Expression for Rosacea

Search GEO for disease gene expression data for Rosacea.

Pathways for Rosacea

Pathways related to Rosacea according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 VEGFA TNF TLR2 S100A8 MMP9 MMP8
2
Show member pathways
13.34 VEGFA TNF MMP9 MMP3 IRF4 IL6
3
Show member pathways
12.83 TNF TLR2 IL6 IL33 IL18 CXCL8
4
Show member pathways
12.72 TNF TLR2 IL6 IL33 IL18 CXCL8
5
Show member pathways
12.6 TNF TLR2 IRF4 IL6 IL18
6
Show member pathways
12.34 TNF IL6 IL18 CXCL8 CCR6
7
Show member pathways
12.33 TLR2 S100A8 CCR6 CAMP
8 12.31 TNF TLR2 IL6 IL18 CXCL8
9 12.3 VEGFA TNF TLR2 MMP9 KDR
10 12.28 MMP9 MMP3 IL6 CXCL8
11 12.27 TNF IL6 IL18 CXCL8
12
Show member pathways
12.27 TNF TLR2 IL6 CXCL8
13
Show member pathways
12.25 TNF KDR IRF4 IL6 IL18 CXCL8
14 12.24 TNF IL6 IL18 CXCL8 CAMP
15
Show member pathways
12.2 TNF TLR2 IL6 CXCL8
16 12.19 VEGFA TNF IL6 CXCL8
17 12.19 VDR TNF TLR2 IL6 IL18 CAMP
18 12.16 VEGFA TNF TLR2 MMP9 IL6
19
Show member pathways
12.14 TNF TLR2 S100A8 MMP9 MMP3 IL6
20 12.08 VEGFA TNF MMP9 KDR GSTM1
21 12.04 TNF IL6 IL18 CXCL8
22 12.03 TNF MMP9 IL6 CXCL8
23 12 TNF MMP9 MMP3 IL6
24
Show member pathways
11.97 TNF TLR2 IL6 IL18
25 11.95 TNF TLR2 IL6 CXCL8
26 11.93 VEGFA TNF IL6 CXCL8
27
Show member pathways
11.92 TNF MMP9 MMP8 MMP3
28 11.78 TNF IRF4 IL33 IL18 CCR6
29 11.77 TNF IL6 CXCL8
30
Show member pathways
11.76 TNF IRF4 CXCL8
31 11.75 TNF IRF4 IL6
32 11.74 VEGFA MMP9 CXCL8
33 11.69 MMP9 IL6 CXCL8
34 11.66 MMP9 MMP3 CXCL8
35 11.66 TNF MMP9 IL6 CXCL8
36 11.57 VEGFA IL6 CXCL8
37 11.54 TNF MMP9 IL6
38 11.52 TNF IL6 IL18 CXCL8
39 11.52 TNF TLR2 IL6 IL18 CXCL8
40 11.5 VDR TNF IL6
41 11.49 TNF TLR2 KLK5 IL18
42 11.47 VEGFA TNF TLR2 MMP3 IL6 IL18
43
Show member pathways
11.43 VEGFA TNF MMP9 MMP3 IL6 CXCL8
44 11.42 TNF TLR2 IL6 IL18 CXCL8
45 11.41 TNF IL6 IL18
46 11.37 MMP9 IL6 CXCL8
47 11.3 TNF IL6 IL33 IL18
48 11.28 VEGFA TNF MMP9 MMP3 IRF4 IL6
49 11.21 TLR2 MMP9 IL18
50 11.17 VEGFA MMP9 KDR

GO Terms for Rosacea

Cellular components related to Rosacea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 VEGFA TNF S100A8 MMP9 MMP8 MMP3
2 extracellular space GO:0005615 9.44 VEGFA TNF S100A8 MMP9 MMP8 MMP3
3 tertiary granule lumen GO:1904724 9.33 MMP9 MMP8 CAMP

Biological processes related to Rosacea according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.18 VEGFA VDR TNF TLR2 IRF4 IL6
2 neutrophil degranulation GO:0043312 10.06 TLR2 S100A8 MMP9 MMP8 CAMP
3 immune response GO:0006955 10.06 TNF TLR2 IL6 IL18 CXCL8 CCR6
4 negative regulation of gene expression GO:0010629 10 VEGFA VDR TNF MMP8 KDR
5 extracellular matrix organization GO:0030198 9.97 TNF MMP9 MMP8 MMP3 KDR
6 positive regulation of protein phosphorylation GO:0001934 9.95 VEGFA TNF MMP9 KDR CAMP
7 inflammatory response GO:0006954 9.95 TNF TLR2 S100A8 IL6 IL18 CXCL8
8 positive regulation of angiogenesis GO:0045766 9.92 VEGFA KDR CXCL8 CAMP
9 cellular response to lipopolysaccharide GO:0071222 9.92 VDR TNF IL6 CXCL8 CAMP
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.88 TNF TLR2 S100A8 IL6 IL18
11 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 VEGFA TNF IL6 IL18
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 TNF IL6 IL18
13 defense response to Gram-positive bacterium GO:0050830 9.83 TNF TLR2 IL6 CRP CAMP
14 humoral immune response GO:0006959 9.82 TNF IL6 CCR6
15 positive regulation of protein complex assembly GO:0031334 9.82 VEGFA TNF MMP3
16 extracellular matrix disassembly GO:0022617 9.81 MMP9 MMP8 MMP3 KLK5
17 positive regulation of gene expression GO:0010628 9.81 VEGFA VDR TNF TLR2 MMP8 IL6
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.8 TNF TLR2 MMP8 IL18
19 collagen catabolic process GO:0030574 9.79 MMP9 MMP8 MMP3
20 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 TNF TLR2 IL18
21 positive regulation of DNA binding GO:0043388 9.77 MMP9 MMP8 IRF4
22 positive regulation of inflammatory response GO:0050729 9.77 TNF TLR2 S100A8 IL33 IL18
23 positive regulation of chemokine production GO:0032722 9.73 TNF TLR2 IL6
24 positive regulation of interleukin-6 production GO:0032755 9.72 TNF TLR2 MMP8 IL6 IL33
25 leukocyte migration involved in inflammatory response GO:0002523 9.67 S100A8 CCR6
26 response to molecule of bacterial origin GO:0002237 9.66 TLR2 CXCL8
27 vascular wound healing GO:0061042 9.65 VEGFA KDR
28 T-helper 17 cell lineage commitment GO:0072540 9.64 IRF4 IL6
29 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.63 VEGFA KDR
30 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.63 VEGFA KDR
31 negative regulation of lipid storage GO:0010888 9.63 TNF IL6 CRP
32 regulation of microglial cell activation GO:1903978 9.61 MMP8 IL6
33 regulation of neuroinflammatory response GO:0150077 9.56 MMP9 MMP8 MMP3 IL6
34 cytokine-mediated signaling pathway GO:0019221 9.56 VEGFA TNF MMP9 MMP3 IRF4 IL6
35 positive regulation of neuroinflammatory response GO:0150078 9.02 TNF MMP8 IL6 IL33 IL18

Molecular functions related to Rosacea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.26 MMP9 MMP8 MMP3 KLK5
2 cytokine activity GO:0005125 9.1 VEGFA TNF IL6 IL33 IL18 CXCL8

Sources for Rosacea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....